Forecast to Publish a Notice of Funding Opportunity for The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required)
The NCI will soon seek applications from institutions to lead early-phase cancer clinical trials within its Experimental Therapeutics Clinical Trials Network, with funding details expected in Summer 2025.
Funder: National Institutes of Health
Due Dates: June 30, 2026
Funding Amounts: Estimated total program funding: $11,800,000; ~6 awards expected; multi-year cooperative agreements
Summary: Supports lead academic organizations in designing, conducting, and analyzing early phase cancer therapeutic clinical trials within the NCI Experimental Therapeutics Clinical Trials Network.
Description
This opportunity, offered by the National Cancer Institute (NCI) at NIH, seeks applications from institutions aiming to serve as Lead Academic Organizations (LAOs) within the Experimental Therapeutics Clinical Trials Network (ETCTN). The ETCTN LAOs are responsible for designing, developing, monitoring, conducting, and analyzing early phase clinical trials (including phase 0, phase 1, phase 2, pilot, and other experimental therapeutic trials) for agents under regulatory sponsorship for New Investigational Drug (IND) applications held by NCI's Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP). Each LAO will both lead its own clinical trials and participate in trials led by other organizations in the network.
